



Baker Research Online
<http://library.bakeridi.edu.au>

This is the postprint version of the work. It is the manuscript that was accepted by the journal following peer review. It does not include the publisher's layout and pagination.

Dempsey PC, Blankenship JM, Larsen RN, Sacre JW, Sethi P, Straznicky NE, Cohen ND, Cerin E, Lambert GW, Owen N, Kingwell BA, Dunstan DW. Interrupting prolonged sitting in type 2 diabetes: nocturnal persistence of improved glycaemic control. *Diabetologia* 2017;60(3):499-507.

<http://hdl.handle.net/11187/2693>

Copyright © Springer Verlag. This file is for personal use. Further distribution is not permitted.
The final publication is available at link.springer.com

Article

Interrupting prolonged sitting in type 2 diabetes: nocturnal persistence of improved glycaemic control

Paddy C. Dempsey^{1,2}, Jennifer M. Blankenship³, Robyn N. Larsen¹, Julian W. Sacre¹, Parneet Sethi¹, Nora E. Straznicky¹, Neale D. Cohen¹, Ester Cerin^{1,4,5}, Gavin W. Lambert^{1,2}, Neville Owen^{1,2,6,7}, Bronwyn A. Kingwell^{1,2}, David W. Dunstan^{1,2,8,9,10,11}

¹ Baker IDI Heart and Diabetes Institute, Level 4, 99 Commercial Road, Melbourne, VIC 3004, Australia

² Faculty of Medicine, Nursing and Health Sciences, Central Clinical School, Monash University, Melbourne, VIC, Australia

³ Department of Kinesiology, University of Massachusetts, Amherst, MA, USA

⁴ School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China

⁵ Institute for Health and Ageing, Australian Catholic University, Melbourne, VIC, Australia

⁶ Health Sciences, Swinburne University of Technology, Melbourne, VIC, Australia

⁷ Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia

⁸ Institute of Physical Activity and Nutrition Research, School of Exercise and Nutrition Sciences, Deakin University, Melbourne, VIC, Australia

⁹ Mary MacKillop Institute of Health Research, Australian Catholic University, Melbourne, VIC, Australia

¹⁰ School of Public Health, The University of Queensland, Brisbane, QLD, Australia

¹¹ School of Sport Science, Exercise and Health, The University of Western Australia, Perth, WA, Australia

Corresponding author:

Paddy C. Dempsey
Baker IDI Heart and Diabetes Institute,
Level 4, 99 Commercial Rd,
Melbourne VIC 3004,
Australia
E-mail: paddy.dempsey@bakeridi.edu.au

Received: 25 August 2016 / Accepted: 4 November 2016

Abstract

Aims/hypothesis We aimed to examine the effect of interrupting 7 h prolonged sitting with brief bouts of walking or resistance activities on 22 h glucose homeostasis (including nocturnal-to-following morning hyperglycaemia) in adults with type 2 diabetes.

Methods This study is an extension of a previously published randomised crossover trial, which included 24 inactive overweight/obese adults with type 2 diabetes (14 men; 62 ± 6 years) who completed three 7 h laboratory conditions, separated by 6–14 day washout periods: SIT: (1) uninterrupted sitting (control); (2) light-intensity walking (LW): sitting plus 3 min bouts of light-intensity walking at 3.2 km/h every 30 min; (3) simple resistance activities (SRA): sitting plus 3 min bouts of simple resistance activities (alternating half-squats, calf raises, brief gluteal contractions and knee raises) every 30 min. In the present study, continuous glucose monitoring was performed for 22 h, encompassing the 7 h laboratory trial, the evening free-living period after leaving the laboratory and sleeping periods. Meals and meal times were standardised across conditions for all participants.

Results Compared with SIT, both LW and SRA reduced 22 h glucose [SIT: 11.6 ± 0.3 mmol/l, LW: 8.9 ± 0.3 mmol/l, SRA: 8.7 ± 0.3 mmol/l; $p < 0.001$] and nocturnal mean glucose concentrations [SIT: 10.6 ± 0.4 mmol/l, LW: 8.1 ± 0.4 mmol/l, SRA: 8.3 ± 0.4 mmol/l; $p < 0.001$]. Furthermore, mean glucose concentrations were sustained at a lower level nocturnally until the next morning following the intervention for both LW and SRA (waking glucose both -2.7 ± 0.4 mmol/l compared with SIT; $p < 0.001$).

Conclusions/interpretation Interrupting 7 h prolonged sitting time with either LW or SRA reduced 22 h hyperglycaemia. The glycaemic improvements persisted after these laboratory conditions and nocturnally, until waking the following morning. These findings may have

implications for adults with relatively well-controlled type 2 diabetes who engage in prolonged periods of sitting, for example, highly desk-bound workers.

Trial registration: anzctr.org.au ACTRN12613000576729

Funding: This research was supported by a National Health and Medical Research Council (NHMRC) project grant (no. 1081734) and the Victorian Government Operational Infrastructure Support scheme.

Keywords Cardiometabolic risk; Diabetes; Glycaemic control; Glycaemic variability; Nocturnal glycaemia; Physical activity; Resistance exercise; Sedentary behaviour; Sitting; Walking

Abbreviations

AUC _{total}	Total area under the curve
CGM	Continuous glucose monitor
CONGA-1	Continuous overall net glycaemic action at 1 hour
iAUC	Incremental AUC
LW	Sitting interrupted with 3 min bouts of light-intensity walking
MAGE	Mean amplitude of glycaemic excursion
SD _{glucose}	SD of glucose
SIT	Uninterrupted sitting
SRA	Sitting interrupted with 3 min bouts of simple resistance activities

Introduction

Postprandial hyperglycaemia is linked to an increased risk of micro- and macro-vascular complications, particularly in individuals with type 2 diabetes [1, 2]. Even with anti-hyperglycaemic medications, adults with type 2 diabetes can spend between 25 and 40% of the day, and approximately 2 h on average nocturnally, in a state of hyperglycaemia (blood glucose >10 mmol/l) [3]. Moreover, the frequency and magnitude of glucose fluctuations and oscillations throughout the day (glycaemic variability) may also increase the risk of diabetic and cardiovascular complications independently of overall blood glucose levels [4-6]. Therefore, identifying safe and effective ways to manage postprandial glucose homeostasis is imperative within type 2 diabetes management.

Despite the multitude of benefits of regular moderate-to-vigorous exercise for improving glycaemic control and insulin sensitivity in type 2 diabetes patients [7], many adults with type 2 diabetes do not meet physical activity recommendations [8]. Indeed, population studies demonstrate that adults can spend over 65% of their waking hours in sedentary behaviours (involving prolonged sitting), while only ~5% of waking hours are spent in moderate-to-vigorous physical activity [9, 10]. These large volumes of sedentary time are associated with higher type 2 diabetes risk, even after controlling for leisure-time spent in moderate-to-vigorous physical activity [11, 12].

Recent experimental evidence suggests that reducing and interrupting prolonged sitting with brief bouts (<5 min) of standing or light ambulation has acute beneficial effects on postprandial glucose and insulin concentrations in healthy, overweight/obese adults and in those with impaired glucose regulation [13-15]. We recently expanded upon these findings, providing the first laboratory evidence in patients with type 2 diabetes that regular brief interruptions to high amounts of prolonged sitting (7 h) with light activities (3 min bouts

every 30 min) significantly improved concurrent postprandial glucose, insulin and C-peptide responses following standardised mixed-meals [16]. Further, in healthy-active young adults, a day of light-intensity physical activity and minimal sitting (<6 h) improved whole body insulin action the following morning, compared with a day of prolonged (16 h) sitting [17]. Altogether, these studies highlight the detrimental effects of prolonged sitting and the potential benefits of reducing and interrupting overall sitting time. However, it remains unclear whether benefits in type 2 diabetes patients: (1) persist beyond the immediate 7 h intervention period (i.e. nocturnally until waking the subsequent morning); and (2) extend to reductions in glycaemic variability (i.e. the frequency and magnitude of glucose oscillations and fluctuations).

Using continuous glucose monitoring technology to better characterise and understand meal-to-meal and temporal glucose homeostasis, glycaemic variability, and potential carryover effects beyond the controlled-laboratory setting [16], we compared the impact of 7 h prolonged sitting with 7 h sitting interrupted with brief bouts of light-intensity walking or simple resistance activities on 22 h glucose homeostasis in adults with type 2 diabetes. We hypothesised that interrupting prolonged sitting time over 7 h would lower postprandial glucose responses, 22 h hyperglycaemia and glycaemic variability, and that improvements in glycaemic control would be sustained nocturnally, until the morning following the intervention.

Methods

Participants As previously reported [16], non-smoking men and women (BMI 25–40 kg/m²; aged 35–75 years; with type 2 diabetes [diet or metformin-controlled, ≥3 months duration, based on American Diabetes Association diagnostic criteria [18]]) were recruited. Participants were excluded if they self-reported sitting <5h/day and/or were meeting physical

activity guidelines (≥ 150 min/week of moderate-intensity exercise). The study was approved by the Institutional Human Research Ethics Committee and all participants provided written informed consent.

Study design This randomised crossover trial was undertaken at the Baker IDI Heart and Diabetes Institute between October 2013 and November 2014. Detailed screening and testing procedures have been described previously [16]. The continuous glucose monitor (CGM) data reported here were a pre-specified secondary outcome of the study and have not been previously reported. In brief, participants attended the laboratory on five separate occasions: visit 1, medical screening visit; visit 2, familiarisation visit; and visits 3–5, three acute 8 h trial condition visits in a randomised order, each separated by 6–14 days. Trial condition order was randomised by a third party (block randomisation with balanced block sizes) and stratified by sex.

Experimental protocol and laboratory conditions As previously reported [16], on trial condition days, participants arrived at the laboratory at ~07:00 hours, after a 12h fast. For 48 h prior to trial condition days, participants were asked to abstain from caffeine, alcohol and structured moderate-to-vigorous physical activities (i.e. no physical activity beyond that of daily living). Each laboratory condition was an 8 h total duration (~08:00–16:00 hours; Fig. 1) and commenced with a 60 min ‘steady-state’ period (from –1 h to 0 h), after which participants consumed standardised breakfast (at 0 h) and lunch (at 3.5 h) meals, with the time taken to consume (<20 min per meal) replicated in subsequent conditions. Participants began the following experimental protocols, in a randomised order, after the breakfast meal: (1) uninterrupted sitting (SIT); (2) sitting interrupted with 3 min bouts of light-intensity walking (LW; 3.2 km/h) every 30 min; and (3) sitting interrupted with 3 min bouts of simple resistance activities (SRA) every 30 min (comprising 20 s body weight half-squats, 20 s calf

raises, 20 s gluteal contractions and knee raises; repeated three times in sequential order while mimicking a standardised video recording).

Participants sat upright in a comfortable chair throughout each 8 h laboratory condition and were instructed to minimise excessive movement, only rising from the chair to void. Standardised lavatory visits were incorporated into the protocol to minimise unscheduled physical activity; however, additional lavatory visits were permitted. Participants complied with the respective laboratory 8 h condition protocols under direct supervision from research staff.

At the end of each 8 h laboratory visit (~16:00 hours), participants returned home and were asked to consume their standardised evening meal between 19:00–20:00 hours that evening and sleep at their usual time, keeping these timings as consistent as possible for subsequent trial conditions. As per the 48 h prior to each trial condition, participants were asked to continue to abstain from caffeine and alcohol until after removing the CGM the following morning.

Standardisation of diet, medications and physical activity To minimise diet-induced variability during testing periods, meals were standardised between conditions and individualised to meet 33% of daily estimated energy requirements using the Schofield equation and a physical activity factor of 1.5 [19]. The target macronutrient profile was 12–15% energy from protein, 55–58% from carbohydrate and 29–31% from fat [16]. Evening meal packs were provided for participants to consume at home (between 19:00–20:00 hours) on the evening of, and prior to each experimental condition. Prescribed medications were continued throughout the study.

Participants were instructed to maintain their normal physical activities after leaving the laboratory, but refrain from any structured moderate-to-vigorous physical activity until after the removal of the CGM (see below) the following morning. To objectively measure any possible postural compensatory behaviour during the evening of the test day that may have occurred as a result of the trial condition, an activPAL3 tri-axial physical activity monitor (PAL-technologies, Glasgow, Scotland, UK) was worn on the right thigh during each condition for 22 h for objective measurements of time spent sitting, standing and stepping, both inside and outside the laboratory [20]. As previously described [16], anthropometric, biochemical and dietary data and accelerometer-derived physical activity data were not significantly different 48 h before each trial condition.

Continuous glucose monitoring For the present study, a CGM (iPro2 CGM with Enlite sensors; Medtronic, Northridge, CA, USA) was inserted immediately upon arrival at the laboratory (07:00–07:15 hours) by trained research personnel into the subcutaneous fat in the lumbar region, and secured using a thin clear film according to the manufacturer's instructions. Once inserted, the CGM recorded interstitial fluid glucose concentrations every 5 min for 22 h (data collection occurred from 09:00 hours on the trial day until 07:00 hours the following morning). For subsequent conditions, new sensors were inserted within approximately 2 cm of the initial insertion site. To calibrate the CGM, capillary (fingerstick) blood glucose samples were collected at six standardised times during the 22 h period (three in the laboratory and three at home) according to the manufacturer's instructions, using a commercial, time-stamped glucometer (Abbott Freestyle Optium, Witney, Oxfordshire, UK). Participants were provided with verbal and written instructions for the collection of capillary measurements at home and the times of collection (which were later confirmed in the laboratory using the glucometer's stored memory function). Validation studies have

demonstrated good agreement between individual glucose measurements derived via Enlite sensors and venous blood [21, 22], along with test-retest reliability [23].

Data handling and statistical analyses Physical activity monitor data (activPAL events files) were processed in SAS 9.4 (SAS Institute, Cary, NC, USA) to analyse time spent sitting, standing and stepping for both the trial condition (laboratory), and the post-trial condition until bedtime (evening) periods. A modified algorithm was used to identify participant sleep time as ≥ 20 min of continuous sitting/lying occurring at or following self-reported bedtime [24]. Invalid/non-wear days were identified as containing < 10 h of waking wear, $\geq 95\%$ of waking wear time spent in any one activity or < 500 steps [25].

CGM data were analysed using the R statistical software package, version 3.1.2 (www.r-project.org, accessed 17 Feb 2016). Data were summarised into three different time periods: (1) overall (waking and nocturnal hours over the 22h trial period); (2) meal times; and (3) nocturnal. To summarise the overall CGM data, we calculated 22 h mean glucose and total area under the curve (AUC_{total}) using the trapezoidal method from a baseline concentration of zero. Time in hyperglycaemia was quantified as time spent with glucose > 10 mmol/l. A number of common indices of glycaemic variability (CV [%], SD of glucose [$SD_{glucose}$], mean amplitude of glycaemic excursion [MAGE] and continuous overall net glycaemic action at 1 hour [CONGA-1]) were also calculated for the 22 h period (see electronic supplementary material (ESM) Methods for details).

Meal times for breakfast, lunch and dinner were defined as 15 min before the meal until 3 h after the end of the meal. The data period during which participants were eating the meal was excluded from analysis. We calculated the baseline glucose concentration before each meal (mean of glucose during the 15 min before the meal). To summarise each meal response we

calculated the net incremental area under the curve (iAUC) because it has been shown to be more reflective of the glucose response to a meal than AUC_{total} [26]. Net iAUC was calculated for each meal as total incremental area below the curve, subtracting the area below each pre-meal baseline glucose concentration from that above. Finally, time in hyperglycaemia was calculated for all meal periods.

Nocturnal glucose was defined as the period beginning with activPAL-derived sleep time until self-reported wake time the next day. Nocturnal glucose was quantified using mean glucose, AUC_{total} and time in hyperglycaemia. Waking glucose was defined as the average of the final 15 min of the 22 h continuous glucose monitoring period for all participants.

Generalised linear mixed-models with random intercepts were used to evaluate the differential effects of the experimental conditions on all summary outcome variables using Stata 12 (StataCorp, College Station, TX, USA). Residuals were examined for serial correlation, heteroscedasticity and normality. Substantial departures from model assumptions were not observed. A two-tail probability level of 0.05 was adopted. Data are expressed as mean \pm SEM in text unless otherwise stated. All models were adjusted for potential covariates explaining residual outcome variance (age, BMI and sex), including preprandial values and period effects (treatment order) for glucose outcomes. Glycaemic variability measures were additionally adjusted for mean glucose concentrations. Meal-by-condition, sex-by-condition and BMI-by-condition interaction tests were also performed for mean glucose, iAUC and time in hyperglycaemia.

Results

Participant characteristics Twenty-four participants (see Table 1 for participant characteristics) were randomised and completed all trial conditions. Aside from BMI (31.5

kg/m² vs 35.2 kg/m² for men vs women; $p=0.005$), there were no significant differences in sex-related baseline variables or medications [16].

Postural allocation and meal/sleep periods Data from the activPAL are shown in Table 2. By design, the LW and SRA conditions saw greater proportions of the laboratory period spent standing or stepping compared with SIT. In turn, LW and SRA were characterised by greater allocations of time to stepping and standing, respectively. During the evening period, there were no significant differences in time spent seated, standing or stepping between trial conditions.

Recorded dinner, bedtime and waking times were between 18:15 and 20:30 hours (mean: 19:15 hours), 20:38 and 02:21 hours (mean: 22:28 hours), and 05:45 and 09:20 hours (mean: 07:01 hours), respectively (data not shown). Mean (\pm SD) within-participant differences in dinnertime (23 ± 20 min), bedtime (48 ± 32 min) and waking time (24 ± 16 min) were not significantly different between trial conditions, nor were mean sleep durations (SIT: 8h 12 min \pm 55 min; LW: 7h 55 min \pm 57 min; SRA: 8h 13 min \pm 56 min; $p>0.1$ for all; data not shown).

Glucose homeostasis and glycaemic variability over 22 h An overview of the mean 22 h glycaemic profiles for all participants by trial condition is presented in Fig. 1. Over the entire 22 h period, mean glucose concentrations, cumulative AUC_{total} and time spent in hyperglycaemia (>10 mmol/l) were all significantly reduced during the LW and SRA conditions compared with SIT (Table 3). Measures of glycaemic variability (MAGE, CONGA-1 and $SD_{glucose}$) were significantly reduced for the LW and SRA conditions compared with SIT when adjusting for baseline glucose levels and other covariates, but not after additionally adjusting for mean 22 h glucose levels (ESM Table 1, Model 1 vs Model 2).

Similarly, CV (%) was not significantly different between conditions. No significant differences were observed between LW and SRA for any glycaemic outcomes. No hypoglycaemic episodes (i.e. glucose <3.9 mmol/l) were observed during any of the trial conditions (data not shown).

Postprandial glycaemic control Mean glucose, iAUC, and time spent in hyperglycaemia were all significantly lower for the LW and SRA conditions compared with SIT for each meal (see Fig. 2). A significant meal-by-condition interaction effect was observed for mean glucose and glucose iAUC responses (Fig. 2a,b), but not time in hyperglycaemia (Fig. 2c). While both LW and SRA reduced glucose concentrations for each meal period compared with SIT, the mean glucose and glucose iAUC reductions for breakfast were significantly larger than lunch and dinner ($p<0.001$; Fig. 2a,b). Further, mean glucose and iAUC reductions following the dinner meal were significantly greater for the SRA condition compared with both LW ($p<0.05$; Fig. 2a,b) and SIT ($p<0.05$). No significant sex-by-condition or BMI-by-condition interaction effects were observed for any of the glycaemic variables (data not shown).

Nocturnal glycaemic control Mean glucose concentrations, AUC_{total} and time spent in hyperglycaemia were all significantly reduced during the sleeping period in the LW and SRA test conditions vs the SIT condition (see Table 3). Mean glucose concentrations were also significantly lower the morning following the intervention for both LW and SRA compared with SIT (-2.7 ± 0.4 mmol/l for both; $p<0.001$; Table 3). No significant differences were observed between LW and SRA.

Discussion

The novel finding in this study is that interrupting high levels of prolonged sitting (7 h) with brief bouts of light-intensity walking and simple resistance activities (3 min every 30 min) significantly lowered 22 h hyperglycaemia, including nocturnal hyperglycaemia, in inactive overweight/obese adults with type 2 diabetes. Importantly, while reductions in postprandial glucose were observed during the 7 h controlled laboratory period, improved glycaemic control persisted into the subsequent free-living evening and sleeping periods until the following morning. An average waking glucose reduction of 2.7 mmol/l was observed for both the LW and SRA conditions compared with prolonged sitting (SIT).

The use of continuous glucose monitoring facilitated the tracking of glucose homeostasis both within the laboratory conditions, and during subsequent free-living and nocturnal periods outside the laboratory (see Fig. 2). Exposure to postprandial hyperglycaemia (>10 mmol/l) was highly prevalent during SIT for the observed 22 h period. Indeed, participants spent some 57% more time in hyperglycaemia over the 22 h for SIT compared with both LW and SRA. For perspective, this duration of time in hyperglycaemia equates to approximately twice that previously reported in individuals with type 2 diabetes on standardised diets while observed in a free-living environment [3, 27, 28]. In addition, time spent in nocturnal hyperglycaemia was some 60% greater for prolonged sitting compared with the activity conditions. These data highlight both the detrimental and persistent nature of high levels of prolonged sitting in type 2 diabetes patients, but also the glycaemic benefits of regularly interrupting high levels of prolonged sitting.

Concordant with the second-meal phenomenon [29], glucose responses across all conditions were lower following the lunch and dinner meals compared to breakfast. Mean reductions in time spent in hyperglycaemia were slightly lower for the dinner meal (though not statistically significant) compared with breakfast and lunch, which could be a consequence of the

breakfast and lunch meals being closer together than lunch and dinner, allowing less time for glucose clearance. Importantly, while all postprandial glucose responses were lower during the activity-breaks conditions compared to prolonged sitting, the most marked reductions were observed following the breakfast meal. This may be attributable to the overall glucose responses being highest for breakfast, but is also suggestive that the timing of activity-breaks, or prolonged sitting, around meals – particularly the first meal of the day coming off an overnight fast – may be an important consideration for reducing glycaemic excursions.

Interestingly, while postprandial glucose excursions were improved with both LW and SRA conditions compared with SIT for each of the three post-meal periods, the postprandial glucose responses following the dinner meal were significantly lower for SRA compared with LW. While the reasons for this are unknown, this finding could be related to the nature of the activity-break intervention (different modality and/or increased intensity/energy expenditure of SRA bouts relative to LW) [16] and/or differential effects on hepatic glucose output or peripheral insulin sensitivity with varying exercise modes [30, 31]. However, such factors would not fully explain why glucose concentrations were generally similar between LW and SRA conditions during both the laboratory and sleeping periods.

This is the first study to report data on glycaemic variability when comparing a bout of prolonged sitting with sitting frequently interrupted with brief bouts of activity in type 2 diabetes. Although the prognostic value of glycaemic variability in type 2 diabetes remains contentious [32] (largely due to the relatively recent advent of continuous glucose monitoring technology, inconsistent findings, and a lack of prospective data) there is evidence to suggest that greater glycaemic variability may be adversely associated with endothelial dysfunction, oxidative stress and diabetic complications [4-6]. In the absence of a gold-standard measure to assess glycaemic variability, and because different indices assess distinct aspects of

glycaemic variability, we computed a range of commonly used measures. While significant reductions in MAGE, CONGA-1 and SD_{glucose} were observed with LW and SRA interventions compared with SIT, these effects were not apparent following statistical adjustment for mean glucose levels. These findings, together with the lack of between-condition differences in per cent CV (which directly normalises for mean glucose), point to a similar *relative* magnitude of glucose fluctuations around lower means for the LW and SRA conditions, rather than less variability *per se*.

The measures used in this study do not permit conclusions on the putative mechanisms responsible for the improvements in glycaemic control. However, in the same participants, we previously reported concurrent attenuations in venous glucose, insulin and C-peptide during the LW and SRA conditions, relative to SIT [16]. The lowering of glucose in spite of lower insulin and C-peptide (indicative of reduced endogenous insulin secretion) with light-activity is suggestive of either enhanced insulin sensitivity and/or a greater reliance on insulin-independent contraction-mediated glucose disposal [30, 33]. Recent investigations appear to offer more support for the role of the skeletal muscle contraction-mediated glucose uptake pathway in improved postprandial glucose metabolism during acute (one day) interventions examining frequent ambulatory interruptions in sitting time [33]. However, these signalling pathways may be differentially altered in type 2 diabetes patients.

A key strength of this study is the randomised crossover design, which incorporated both controlled-laboratory, free-living and nocturnal elements. Participants acted as their own controls, which enhanced both the internal validity and reliability of our data and permitted a smaller sample size. The laboratory trial and subsequent free-living phases were examined with the use of objective, posture-discriminating devices, while participants consumed a standardised, ecologically valid, western-type diet [34]. The continuous activity

measurements, alongside CGM use, enabled us to account for these key activity and dietary behaviours, thereby increasing the experimental rigor of our findings.

When interpreting the findings of this study, it is important to emphasise that while continuous glucose monitoring offers many clinical and research advantages, it is an imperfect surrogate for venous blood glucose. CGM data accuracy may be influenced by numerous factors, including signal stability, physiological differences in interstitial glucose homeostasis, physiological/device lag-times and individual differences. These limitations remain relatively under-researched [21, 35]. While we attempted to best account for the known measurement issues where possible, we note that our CGM data appear to have over-estimated (by about twofold) the quantitative differences between the sitting and active conditions when compared with our previously reported venous glucose data over 7 h [16]. Reasons for this are not readily apparent, however, we do acknowledge that it would have been more desirable to insert the CGM the night prior to each intervention to allow the sensors to fully equilibrate. Consideration of this and the above factors would be prudent in future research.

We also acknowledge that both the prescribed activity/sedentary behaviour during the laboratory phase and the dietary profiles (e.g. macronutrient profile, glycaemic index, meal frequency and size) may not reflect habitual behaviours in sedentary individuals in real-world settings and could have exaggerated the glycaemic differences we observed between trial conditions. With this in mind, an important caveat for this study is that the two activity-break conditions (6 min or ~10% activity per hour) were closer to activity patterns typically observed for sedentary free-living individuals (i.e. ~30–35% activity per hour) [9, 10] compared with the ‘unnatural’ experimental arrangements of our prolonged sitting condition. Although it was important to first establish ‘proof-of-concept’ in a controlled-laboratory

sitting and to accurately describe dose–response variables, 7 h prolonged sitting with only 1–2 toilet breaks, while plausible under some circumstances (e.g. during extended automobile/plane journeys or in those who may be required to carry out uninterrupted desk work to meet deadlines), is likely to be an extreme scenario for much of the population. Consequently, it remains uncertain whether adding additional activity breaks on top of a control (sitting) condition that could be aligned more closely to free-living variations in activity would elicit meaningful glycaemic benefits. Therefore, this requires further investigation.

It will be important to establish the efficacy of these interventions in type 2 diabetes patients with more advanced disease, particularly as such patients are more likely to have poorer glycaemic control, are more likely to experience hypoglycaemic episodes and may be less responsive to exercise-mediated glucose reductions [36]. Nevertheless, our findings have relevance to a majority of those with type 2 diabetes (~80–85%), who are not treated with insulin or insulin combined with other oral glucose-lowering agents [37]. Further, it was also encouraging that no hypoglycaemic events were observed despite marked reductions in postprandial hyperglycaemia during the activity-break conditions used in this study.

As mentioned, future studies should examine the glycaemic effects of interventions that interrupt prolonged sitting in more ecologically relevant, free-living environments (e.g. the workplace) that would be more reflective of habitual sitting patterns. It will also be important to determine the effects of these interventions over longer time-periods (i.e. multiple days or weeks) and the specific mechanisms by which different light-intensity activities improve glycaemic control. Finally, it would be relevant to compare, but also combine, strategically placed frequent interruptions in sitting with structured bouts of morning or evening exercise. This would assist in identifying the doses, timing and patterning of physical activity that are

required to optimize 24 h and postprandial glycaemic control for type 2 diabetes management. In these contexts, a further consideration would be the impact of energy balance, which was not strictly controlled for in this study.

In conclusion, this study demonstrates that interrupting high levels of prolonged unbroken sitting time with brief light-intensity walking or simple resistance activity bouts over 7 h reduces sequential postprandial glucose responses in adults with type 2 diabetes, with glycaemic improvements persisting until the next morning. Although generalisability and longer term efficacy, practicality, and suitability for the workplace and home environment still need to be established, these findings may have implications for adults with relatively well-controlled type 2 diabetes who may engage in prolonged periods of sitting, such as in a workplace setting.

Acknowledgements We gratefully acknowledge the excellent technical assistance from I. Mullis, H. Moon, D. Vizi (Research Nurses) and E. Winkler (for data analyses). Most importantly, we thank the study participants for their time and commitment to the study protocol; this study would not have been possible without them. This work was presented by PCD at the 62nd Annual Scientific Meeting of the American Diabetes Association, Boston, MA, USA on the 26–30 May 2015.

Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.

Funding This research was supported by a NHMRC project grant (no. 1081734) and the Victorian Government OIS scheme. PCD is supported by an Australian Postgraduate Award and a Baker IDI Bright Sparks top up scholarship. GWL, NO, BAK, JWS and DWD are supported by the NHMRC Fellowships scheme. EC is supported by an ARC Future Fellowship (no. FT140100085).

Duality of interest statement The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement PCD conceived, designed and conducted the study, analysed and interpreted the data, and wrote the manuscript. JMB, PS and EC assisted with data cleaning or management and statistical analyses/interpretation. NDC provided clinical support during data collection. JMB, RNL, JWS, NES, NDC, GWL, PS, EC, NO, BAK, DWD assisted in the concept and design of the study and participated in critical revision of the manuscript for intellectual content. All authors approved the final version of this manuscript. PCD and DWD

are the guarantors of this work and, as such, had full access to all the study data and take responsibility for data integrity and accuracy of the data analysis.

.

References

1. The Diabetes Control and Complications Trial (DCCT) Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. *Diabetes*. 1995;44:968-983.
2. Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. *Diabetes Care*. 2011;34:2237-2243.
3. van Dijk JW, Manders RJ, Hartgens F, Stehouwer CD, Praet SF, van Loon LJ. Postprandial hyperglycemia is highly prevalent throughout the day in type 2 diabetes patients. *Diabetes Res Clin Pract*. 2011;93:31-37.
4. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. *Diabetes*. 2008;57:1349-1354.
5. Di Flaviani A, Picconi F, Di Stefano P, et al. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. *Diabetes Care*. 2011;34:1605-1609.
6. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA*. 2006;295:1681-1687.
7. Colberg SR, Albright AL, Blissmer BJ, et al. Exercise and type 2 diabetes: American College of Sports Medicine and the American Diabetes Association: joint position statement. *Exercise and type 2 diabetes*. *Med Sci Sports Exerc*. 2010;42:2282-2303.
8. Zhao G, Ford ES, Li C, Mokdad AH. Compliance with physical activity recommendations in US adults with diabetes. *Diabet Med*. 2008;25:221-227.
9. Matthews CE, Chen KY, Freedson PS, et al. Amount of time spent in sedentary behaviors in the United States, 2003-2004. *Am J Epidemiol*. 2008;167:875-881.
10. Dempsey PC, Owen N, Biddle SJ, Dunstan DW. Managing sedentary behavior to reduce the risk of diabetes and cardiovascular disease. *Curr Diab Rep*. 2014;14:522.
11. Biswas A, Oh PI, Faulkner GE, et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. *Ann Intern Med*. 2015;162:123-132.
12. Wilmot EG, Edwardson CL, Achana FA, et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. *Diabetologia*. 2012;55:2895-2905.
13. Dempsey PC, Owen N, Yates TE, Kingwell BA, Dunstan DW. Sitting less and moving more: Improved glycaemic control for type 2 diabetes prevention and management. *Curr Diab Rep*. 2016;16:114.
14. Chastin SF, Egerton T, Leask C, Stamatakis E. Meta-analysis of the relationship between breaks in sedentary behavior and cardiometabolic health. *Obesity*. 2015;23:1800-1810.
15. Henson J, Davies MJ, Bodicoat DH, et al. Breaking up prolonged sitting with standing or walking attenuates the postprandial metabolic response in postmenopausal women: a randomized acute study. *Diabetes Care*. 2016;39:130-138.
16. Dempsey PC, Larsen RN, Sethi P, et al. Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities. *Diabetes Care*. 2016;39:964-972.
17. Stephens BR, Granados K, Zderic TW, Hamilton MT, Braun B. Effects of 1 day of inactivity on insulin action in healthy men and women: interaction with energy intake. *Metabolism*. 2011;60:941-949.

18. American Diabetes A. Standards of medical care in diabetes--2013. *Diabetes Care*. 2013;36 Suppl 1:S11-S66.
19. Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. *Hum Nutr Clin Nutr*. 1985;39 Suppl 1:5-41.
20. Grant PM, Ryan CG, Tigbe WW, Granat MH. The validation of a novel activity monitor in the measurement of posture and motion during everyday activities. *Br J Sports Med*. 2006;40:992-997.
21. Damiano ER, McKeon K, El-Khatib FH, Zheng H, Nathan DM, Russell SJ. A comparative effectiveness analysis of three continuous glucose monitors: the Navigator, G4 Platinum, and Enlite. *J Diabetes Sci Technol*. 2014;8:699-708.
22. Bailey TS, Ahmann A, Brazg R, et al. Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. *Diabetes Technol Ther*. 2014;16:277-283.
23. Terada T, Loehr S, Guigard E, et al. Test-retest reliability of a continuous glucose monitoring system in individuals with type 2 diabetes. *Diabetes Technol Ther*. 2014;16:491-498.
24. Healy GN, Winkler EA, Owen N, Anuradha S, Dunstan DW. Replacing sitting time with standing or stepping: associations with cardio-metabolic risk biomarkers. *Eur Heart J*. 2015;36:2643-2649.
25. Edwardson CL, Winkler EA, Bodicoat DH, et al. Considerations when using the activPAL monitor in field-based research with adult populations. *J Sport Health Sci*. 2016; doi: 10.1016/j.jshs.2016.02.002
26. Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer FX. The use of areas under curves in diabetes research. *Diabetes Care*. 1995;18:245-250.
27. Praet SF, Manders RJ, Meex RC, et al. Glycaemic instability is an underestimated problem in Type II diabetes. *Clin Sci (Lond)*. 2006;111:119-126.
28. van Dijk JW, Manders RJ, Tummers K, et al. Both resistance- and endurance-type exercise reduce the prevalence of hyperglycaemia in individuals with impaired glucose tolerance and in insulin-treated and non-insulin-treated type 2 diabetic patients. *Diabetologia*. 2012;55:1273-1282.
29. Jovanovic A, Gerrard J, Taylor R. The second-meal phenomenon in type 2 diabetes. *Diabetes Care*. 2009;32:1199-1201.
30. Thyfault JP. Setting the stage: possible mechanisms by which acute contraction restores insulin sensitivity in muscle. *Am J Physiol Regul Integr Comp Physiol*. 2008;294:R1103-1110.
31. Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. *Physiol Rev*. 2013;93:993-1017.
32. Monnier L, Colette C. Glycemic variability: can we bridge the divide between controversies? *Diabetes Care*. 2011;34:1058-1059.
33. Bergouignan A, Latouche C, Heywood S, et al. Frequent interruptions of sedentary time modulates contraction- and insulin-stimulated glucose uptake pathways in muscle: Ancillary analysis from randomized clinical trials. *Sci Rep*. 2016;6:32044.
34. Nutrient reference values for Australia and New Zealand, including recommended dietary intakes. Canberra: National Health and Medical Research Council. Commonwealth of Australia. Department of Health and Ageing, 2006.
35. Wagner J, Tennen H, Wolpert H. Continuous glucose monitoring: a review for behavioral researchers. *Psychosom Med*. 2012;74:356-365.
36. Solomon TP, Malin SK, Karstoft K, Haus JM, Kirwan JP. The influence of hyperglycemia on the therapeutic effect of exercise on glycemic control in patients with type 2 diabetes mellitus. *JAMA Intern Med*. 2013;173:1834-1836.

37. Centers for Disease Control and Prevention. National diabetes statistics report: Estimates of diabetes and its burden in the united states. Atlanta, GA: US Department of Health and Human Services; 2014.

Fig. 1 Mean glucose profiles (\pm SEM) over 22 h during and following each trial condition. The shaded area (prior to 09:00 hours) denotes the 1 h sitting, steady-state period prior to commencing each trial condition. The 3 min activity bouts every 30 min during the LW and SRA interventions are illustrated by the arrows. Standardised meals in the laboratory were consumed at 09:00 hours and 12:30 hours, while mean dinner and bed times were at 19:15 hours and 22:28 hours, respectively (grey vertical dashed lines). The solid black vertical line denotes when participants vacated the laboratory, at ~16:00 hours. The solid grey horizontal line at 10 mmol/l glucose represents the hyperglycaemic threshold. Red shaded area and dashed line, SIT; blue shaded area and solid line, LW; green shaded area and dotted line, SRA

Fig. 2 Difference relative to SIT in (a) glucose net incremental AUC (iAUC), (b) mean glucose and (c) time in hyperglycaemia by meal. Blue opaque circles, LW–SIT, green open squares, SRA–SIT. Data are expressed as mean \pm 95% CI. Mean glucose, iAUC, and time spent in hyperglycaemia were all significantly lower for the LW and SRA conditions compared with SIT for each meal ($p < 0.05$). $^{\dagger}p < 0.001$ vs lunch and dinner meals; $^{\ddagger}p < 0.05$, SRA–SIT vs LW–SIT

Table 1 Participant characteristics

Demographics	Baseline
Sex (male/female)	14/10
Age (y)	62±6
BMI (kg/m ²)	33.0±3.4
Waist circumference (cm)	112.6±9.7
Diabetes duration (y)	6.8±5.1
Ethnicity	
European	20 (83%)
Asian	4 (17%)
Medications, n (%)	
Metformin	23 (96%)
Statin	15 (63%)
Anti-hypertensive	16 (67%)
Metabolic and cardiovascular risk factors	
HbA _{1c} (%) ^b	7.2±0.7
HbA _{1c} (mmol/mol) ^b	55.1±8.0
eGFR (ml min ⁻¹ [1.73m ²] ⁻¹) ^b	86.7±8.1
Fasting glucose (mmol/l) ^a	8.2±1.4
Fasting insulin (pmol/l) ^a	85.9±54.7
Fasting triacylglycerol (mmol/l) ^a	1.9±1.0
Fasting total cholesterol (mmol/l) ^a	4.4±0.8
Fasting LDL-cholesterol (mmol/l) ^a	2.5±0.8
Fasting HDL-cholesterol (mmol/l) ^a	1.1±0.3
Systolic blood pressure (mmHg) ^b	123±14
Diastolic blood pressure (mmHg) ^b	77±9

Data are expressed as mean ± SD, or number (%) where specified

^aMeasured at the screening visit

^bMeasured at the beginning of the first trial condition

eGFR, estimated GFR

Table 2 Total time spent sitting, standing or stepping during the trial conditions, as derived from activPAL

Condition	SIT (min)	LW (min)	SRA (min)
Laboratory			
Wear time	504±3	504±3	502±3
Sitting	499±3	449±3*	453±3*
Standing	4±1	9±1*	30±1*‡
Stepping	2±1	46±1*	19±1*‡
Evening			
Wear time	417±24	418±25	375±24
Sitting	279±11	265±11	262±11
Standing	108±21	119±22	79±21
Stepping	30±2	34.6±3	35±2
Laboratory+Evening			
Wear time	919±29	900±30	839±30*
Sitting	777±17	700±18*	682±17*
Standing	110±21	123±22	105±21
Stepping	32±3	79±3*	52±3*‡

Data are expressed as mean ± SEM

Total time in each activity during the laboratory condition period ('Laboratory'), the period after the laboratory condition ('Evening') and over the entire period until bedtime ('Laboratory+Evening')

* $p < 0.05$ vs SIT; ‡ $p < 0.05$ vs LW

Table 3 Glycaemic control over 22 h and nocturnal glucose levels for each trial condition

Variable	SIT	LW	SRA
22 h			
Mean glucose (mmol/l)	11.6±0.3	8.9±0.3 [†]	8.7±0.3 [†]
AUC _{total} (mmol/l × h)	254.9±6.7	194.7±6.6 [†]	191.5±6.6 [†]
Time in hyperglycaemia (h)	14.7±0.9	6.3±0.8 [†]	6.3±0.9 [†]
Sleeping ^a			
Mean glucose (mmol/l)	10.6±0.4	8.1±0.4 [†]	8.3±0.4 [†]
AUC _{total} (mmol/l × h)	86.9±3.7	64.6±3.6 [†]	68.0±3.7 [†]
Time in hyperglycaemia (h)	4.7±0.4	1.4±0.4 [†]	1.8±0.4 [†]
Waking glucose (mmol/l)	10.3±0.3	7.6±0.3 [†]	7.6±0.3 [†]

Data are expressed as mean ± SEM

^aSleeping is the time period from bedtime until the end of the 22 h period

[†] $p < 0.001$ vs SIT